12-1 Month Momentum % is the total return of the stock from 12-month ago to 1-month ago. As of today (2024-04-16), Puma Biotechnology's 12-1 Month Momentum % is 65.56%.
The industry rank for Puma Biotechnology's 12-1 Month Momentum % or its related term are showing as below:
PBYI's 12-1 Month Momentum % is ranked better than 87.6% of 1484
companies
in the Biotechnology industry
Industry Median: -25.15
vs PBYI: 65.56
Competitive Comparison
For the Biotechnology subindustry, Puma Biotechnology's 12-1 Month Momentum %, along with its competitors' market caps and 12-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Puma Biotechnology 12-1 Month Momentum % Distribution
For the Biotechnology industry and Healthcare sector, Puma Biotechnology's 12-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Puma Biotechnology's 12-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 12-1 Month Momentum % measures the total return to a stock over the past twelve months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Puma Biotechnology 12-1 Month Momentum % Related Terms
Thank you for viewing the detailed overview of Puma Biotechnology's 12-1 Month Momentum % provided by GuruFocus.com. Please click on the following links to see related term pages.
Puma Biotechnology (Puma Biotechnology) Business Description
Puma Biotechnology Inc is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. The company in-licenses the global development and commercialization rights to PB272 (neratinib, oral), PB272 (neratinib, intravenous) and PB357. Neratinib, oral was approved by the U.S. FDA in 2017 for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, following adjuvant trastuzumab-based therapy, and is marketed in the US as NERLYNX.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
PBYI has been successfully added to your